ABSTRACT. Lung cancer is the most common cancer occurring worldwide. The human X-ray repair complementing group 1 (XRCC1) gene is one of the most important candidate genes that influence the susceptibility to lung cancer. The objective of this study was to analyze the potential association between the c.1804C>A genetic variant of XRCC1 and lung cancer susceptibility. A total of 703 subjects were recruited for this study. Genotyping of c.1804C>A genetic variant was performed using the created restriction site-polymerase chain reaction. Statistically significant differences in allele frequencies and genotype were found between lung cancer patients and cancer-free controls. The genotype AA was statistically associated with the increased risk of lung cancer when compared to the wild genotype, CC, and the carrier genotype, CA/CC (AA vs CC: OR = 2.71, 95%CI = 1.57-4.67, P < 0.001; AA vs CA/CC: OR = 2.54, 95%CI = 1.50-4.29, P < 0.001). The allele A likely contributes to the susceptibility to lung cancer (A vs C: OR = 1.47, 95%CI = 1.17-1.84, P = 0.001). Our data indicates that the c.1804C>A genetic variant of XRCC1 is statistically associated with the susceptibility to lung cancer in the Chinese population.
INTRODUCTION
Lung cancer is a common cancer and the leading cause of cancer-related deaths, worldwide. More than one million people die from this disease each year (Guilbert, 2003; Siegel et al., 2012; Yuan et al., 2013a) . It is still associated with poor survival, and the overall five-year survival rate is only 15% in the United States and even lower in China (Parkin et al., 2005; Yin et al., 2009a; Cui et al., 2012) . Many factors affect the development of lung carcinogenesis, and the exact mechanism of lung cancer remains poorly understood. It is generally accepted that genetic factors play key roles in the pathogenesis of lung cancer. Previous studies reported that the human X-ray repair complementing group 1 (XRCC1) gene is one of the most important candidate genes for influencing susceptibility to lung cancer (Hao et al., 2006; Giachino et al., 2007; López-Cima et al., 2007; Sreeja et al., 2008; Chang et al., 2009; Kalikaki et al., 2009; Wang et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Li et al., 2011; Qian et al., 2011; Chen et al., 2012; Cui et al., 2012; Guo et al., 2013) . The potential associations between lung cancer and multiple genetic variants of XRCC1 in different populations have been reported (Hao et al., 2006; Giachino et al., 2007; López-Cima et al., 2007; Improta et al., 2008; Sreeja et al., 2008; Chang et al., 2009; Kalikaki et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Qian et al., 2011; Cui et al., 2012; Guo et al., 2013) . Several genetic variants, including arginine (Arg) 194 tryptophan (Trp), Arg 280 histidine (His) and Arg399 glutamine (Gln), were significantly associated with the susceptibility to lung cancer (Giachino et al., 2007; López-Cima et al., 2007; Sreeja et al., 2008; Kalikaki et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Qian et al., 2011; Guo et al., 2013) . However, the potential association between the XRCC1 c.1804C>A genetic variant and lung cancer susceptibility has not been analyzed. Considering the importance of XRCC1 genetic variants in the development of lung cancer, we hypothesized that the c.1804C>A genetic variant is associated with lung cancer susceptibility, and we evaluated the influence of this variant on the susceptibility to lung cancer by association analysis.
MATERIAL AND METHODS

Study populations
In total, 348 lung cancer patients and 355 cancer-free control patients were recruited from the First Affiliated Hospital of Zhengzhou University (Henan, China) between February 2009 and November 2012. All participants were unrelated Chinese people with Han ethnicity and lived in Zhengzhou city, Henan province of China. Patients with lung cancer were histologically confirmed and diagnosed by doctors. Cancer-free control patients were frequency-matched by sex and age to lung cancer patients. Those with a history of lung cancer or other medical diseases were excluded. 
Genotyping
Venous blood was collected from each subject. Genomic DNA was extracted using the AxyPrep Blood Genomic DNA Miniprep Kit (Axygen, Union City, CA). According to the reference DNA and mRNA sequences of human XRCC1 (GenBank IDs: NC_000019.9 and NM_006297.2), we designed the specific polymerase chain reaction (PCR) primers using Primer Premier 5.0 software (Wu et al., 2005) . Table 2 shows the primers sequences, annealing temperature, amplification regions and sizes. Each PCR was carried out in a 20-µL total volume containing 50 ng template DNA, 1X buffer (Tris-HCl 100 mM, pH 8.3; KCl 500 mM), 0.25 µM primers, 2.0 mM MgCl 2 , 0.25 mM dNTPs (Bioteke Corporation, Beijing, China), and 0.5 U Taq DNA polymerase (Promega, Madison, WI, USA). The PCR cycling conditions were as follows: initial denaturation at 94°C for 5 min, followed by 32 cycles of 94°C for 30 s, 65.0°C for 30 s, 72°C for 30 s, and a final extension at 72°C for 5 min. The genotyping of the c.1804C>A genetic variant was performed using the created restriction site-polymerase chain reaction (CRS-PCR) (Yuan et al., 2013b) . In this method, one of the primers contained a nucleotide mismatch, which enables the use of restriction enzymes for discriminating sequence variations (Haliassos et al., 1989; Zhao et al., 2003; Yuan et al., 2012; Yuan et al., 2013b,c) . The amplified PCR products (10 µL) were digested with 5 units of MaeII (MBI Fermentas, St. Leon-Rot, Germany) at 37°C for 10 h. The digested products were separated using 2.5% agarose gel and visualized under UV light after staining with ethidium bromide. To verify the results of CRS-PCR analyses, 10% of the samples were randomly selected and re-analyzed by DNA sequencing (ABI3730xl DNA Analyzer, Applied Biosystems, Foster City, CA). 
Statistical analyses
All statistical analyses were assessed using the Statistical Package for Social Sciences software (SPSS, Windows version release 15.0; SPSS Inc.; Chicago, IL, USA). HardyWeinberg equilibrium (HWE) of the frequencies of genotype/allele, and the differences of demographic clinical characteristics between cases and controls were evaluated using the chisquared (χ 2 ) test. The potential association of c.1804C>A genetic variant with lung cancer susceptibility was assessed by unconditional logistic regression model using the odds ratios (ORs) with the 95% confidence intervals (95%CIs). A P value < 0.05 was considered to be statistically significant.
RESULTS
General characteristics
The demographic clinical characteristics of 348 lung cancer patients and 355 cancerfree control patients are shown in Table 1 . No statistically significant difference was found between lung cancer patients and cancer-free control patients with regard to sex, age, smoking status and pack-years (P > 0.05).
XRCC1 genetic variant identification
We genotyped the XRCC1 c.1804C>A genetic variant using CRS-PCR and DNA sequencing. Our DNA sequence analyses indicated that this genetic variant is a nonsynonymous mutation, which was caused by C to A mutations in exon 17 of human XRCC1. The mutation has resulted into a proline (Pro) to threonine (Thr) amino acid substitution in the polypeptide (p.Pro602Thr, Reference sequences GenBank IDs: NC_000019.9, NM_006297.2 and NP_006288.2). The MaeII restriction enzyme was selected to digest the PCR products, and then three genotypes were observed: CC (205 bp), CA (205, 187 and 18 bp) and AA (187 and 18 bp, Table 2 ). The frequencies of allelic and genotypic are shown in the Table 3 . We found that the frequencies of allele C and genotype CC were maximums in the studied populations. Statistically significant differences were detected between the allele frequencies of lung cancer patients (C, 65.95%; A, 34.05%) and cancer-free control patients (C, 73.94%; A, 26.06%; χ 2 = 10.6961, P = 0.0011). The frequencies of different genotypes in lung cancer patients (CC, 46.26%; CA, 39.37%; AA, 14.37%) were statistically significant different from the frequencies in cancer-free control patients (CC, 54.08%; CA, 39.72%; AA, 6.20%; χ 2 = 13.6005, P = 0.0011, Table 4 ). Results from the chi-squared (χ 2 ) test indicated that the distributions of genotypes in the studied subjects were in accordance with the HWE (all P > 0.05, Table 3 ). 
XRCC1 genetic variant associated with lung cancer risk
The potential association of the XRCC1 c.1804C>A genetic variant with lung cancer risk is summarize in Table 4 . We found that there were statistically significant risk of lung cancer in the homozygote phenotype comparison (AA versus vs CC: OR = 2.71, 95%CI = 1.57-4.67, χ 2 = 13.56, P < 0.001), dominant model (AA/CA vs CC: OR = 1.37, 95%CI = 1.02-1.84, χ 2 = 4.29, P = 0.038), recessive model (AA vs CA/CC: OR = 2.54, 95%CI = 1.50-4.29, χ 2 = 12.74, P < 0.001) and allele contrast (A vs C: OR = 1.47, 95%CI = 1.17-1.84, χ 2 = 10.69, P = 0.001, Table 4 ). OR = odds ratio; CI = confidence interval; vs = versus. 
DISCUSSION
Lung cancer is global health problem that causes high incidence and high mortality rate. There is increasing evidence that lung cancer is a polygenic and common, malignant solid cancer resulting from complex interactions between environmental and genetic factors. The genetic factors include candidate genes that might play roles functions in the susceptibility to lung cancer. The XRCC1 gene is an important candidate gene for influencing lung cancer susceptibility (Hao et al., 2006; Giachino et al., 2007; López-Cima et al., 2007; Sreeja et al., 2008; Chang et al., 2009; Kalikaki et al., 2009; Wang et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Li et al., 2011; Qian et al., 2011; Chen et al., 2012; Cui et al., 2012; Guo et al., 2013) . In the present study, the influence of the XRCC1 c.1804C>A genetic variant on the susceptibility to lung cancer in Chinese Han population was evaluated by association analysis in 348 lung cancer patients and 355 cancer-free control patients. We found statistically significant differences in the frequencies of allele and genotype between lung cancer patients and cancer-free control patients (Table 3) . Compared to the wild genotype, CC, and the heterozygous genotype, CA/CC, the genotype, AA, was significantly associated with the increased risk of lung cancer (Table 4 ). Our data suggested that the allele C contributes to reduced lung cancer susceptibility, and the genotype CC is associated with a protection factor from lung cancer (Table 4) . Previously published studies, which reported the influence of several genetic variants in XRCC1 (such as Arg194Trp, Arg280His and Arg399Gln) on the risk of lung cancer, are consistent with our findings that genetic variants in XRCC1 genetically impact lung cancer (Giachino et al., 2007; López-Cima et al., 2007; Sreeja et al., 2008; Chang et al., 2009; Kalikaki et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Qian et al., 2011; Chen et al., 2012; Guo et al., 2013) . These genetic variants likely affect the function of XRCC1 in base excision DNA repair pathway, which is significantly associated with lung cancer risk (Hao et al., 2006; Giachino et al., 2007; López-Cima et al., 2007; Sreeja et al., 2008; Kalikaki et al., 2009; Yin et al., 2009a,b; Butkiewicz et al., 2011; Qian et al., 2011) . The c.1804C>A genetic variant may be linked to these known non-synonymous genetic variants, and may play similar functions in the development of lung cancer. Our findings demonstrate that this genetic variant may be used as a molecular marker for evaluating the risk of lung cancer. Future functional investigations on larger and different ethnic populations are necessary to confirm these findings and to clarify the underlying molecular mechanisms and pathophysiology in lung cancer.
